Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US 2020-01-08 08:00
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting 2019-12-10 16:00
Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-LAG-3 Monoclonal Antibody in China 2019-12-06 08:00
Innovent Presents Co-developed Cancer-Fighting Tyvyt(R) (Sintilimab Injection) at CIIE 2019 with Eli Lilly 2019-12-02 09:37
Innovent Biologics Announces FDA Acceptance of NDA for Pemigatinib in Patients with Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements 2019-12-02 08:00
Tyvyt (Sintilimab Injection), an Innovative PD-1 Inhibitor Jointly Developed by Innovent and Lilly, is Included in the New Catalogue of National Reimbursement Drug List (NRDL) 2019-11-28 12:10
Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-PD-1/HER2 Bispecific Antibody in China 2019-11-27 07:50
Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma 2019-10-21 08:00
Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors 2019-10-10 15:55
Innovent Biologics Announces a New Placement Raised HK$2,351.33 Million 2019-10-04 16:11
Innovent Provides Update on Two Studies of IBI301 (Rituximab Biosimilar) in the Treatment of CD20-positive Lymphoma at Annual Meeting of CSCO 2019-09-20 14:30
Innovent Provides Update on the Results of IBI305 for the First-line Treatment of Advanced Non-squamous Cell Lung Cancer by Oral Presentation at CSCO 2019-09-19 16:36
Innovent Biologics Study Results of IBI303 in Patients with Ankylosing Spondylitis was Published in "The Lancet Rheumatology" 2019-08-30 17:38
Innovent Reports Interim Results for Fiscal Year 2019 2019-08-29 08:39
Innovent and Shenogen Announce Collaboration to Evaluate Tyvyt® (Sintilimab injection) in Combination with SNG1005 for the Treatment of Patients with Advanced Cancer 2019-08-06 08:00
First Patient Dosed in Sintilimab and Anti-VEGF Monoclonal Antibody IBI305 with Chemotherapy in Patients with EGFR-mutant Non-squamous NSCLC who have Progressed from Prior EGFR-TKI Treatment 2019-07-25 08:16
NMPA Accepts New Drug Application for IBI301, a Biosimilar Product Candidate of Rituximab (MabThera/Rituxan) 2019-06-27 12:21
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at 2019 ASCO and EHA Annual Meetings 2019-06-18 08:00
Innovent provides Update on the Results of Sintilimab for the Treatment of Extranodal NK/T Cell Lymphoma by Oral Presentation at ASCO 2019-06-05 08:00
Innovent Provides Updates on Extended Follow-up on Sintilimab for Relapsed/Refractory Classical Hodgkin's Lymphoma 2019-06-04 08:00
1 14 15 16 17 18